miR-21	NN
mediates	VBZ
fibrogenic	JJ
activation	NN
of	IN
pulmonary	JJ
fibroblasts	NNS
and	CC
lung	NN
fibrosis	NN
.	.

Uncontrolled	JJ
extracellular	JJ
matrix	NN
production	NN
by	IN
fibroblasts	NNS
in	IN
response	NN
to	TO
tissue	NN
injury	NN
contributes	VBZ
to	TO
fibrotic	JJ
diseases	NNS
,	,
such	JJ
as	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
,	,
a	DT
progressive	JJ
and	CC
ultimately	RB
fatal	JJ
process	NN
that	WDT
currently	RB
has	VBZ
no	DT
cure	NN
.	.

Although	IN
dysregulation	NN
of	IN
miRNAs	NNP
is	VBZ
known	VBN
to	TO
be	VB
involved	VBN
in	IN
a	DT
variety	NN
of	IN
pathophysiologic	JJ
processes	NNS
,	,
the	DT
role	NN
of	IN
miRNAs	NNS
in	IN
fibrotic	JJ
lung	NN
diseases	NNS
is	VBZ
unclear	JJ
.	.

In	IN
this	DT
study	NN
,	,
we	PRP
found	VBD
up-regulation	NN
of	IN
miR-21	NN
in	IN
the	DT
lungs	NNS
of	IN
mice	NNS
with	IN
bleomycin-induced	JJ
fibrosis	NN
and	CC
also	RB
in	IN
the	DT
lungs	NNS
of	IN
patients	NNS
with	IN
IPF	NN
.	.

Increased	VBN
miR-21	NN
expression	NN
was	VBD
primarily	RB
localized	JJ
to	TO
myofibroblasts	NNS
.	.

Administration	NN
of	IN
miR-21	NN
antisense	JJ
probes	NNS
diminished	VBD
the	DT
severity	NN
of	IN
experimental	JJ
lung	NN
fibrosis	NN
in	IN
mice	NNS
,	,
even	RB
when	WRB
treatment	NN
was	VBD
started	VBN
5-7	CD
d	NN
after	IN
initiation	NN
of	IN
pulmonary	JJ
injury	NN
.	.

TGF-beta1	NN
,	,
a	DT
central	JJ
pathological	JJ
mediator	NN
of	IN
fibrotic	JJ
diseases	NNS
,	,
enhanced	VBD
miR-21	NN
expression	NN
in	IN
primary	JJ
pulmonary	JJ
fibroblasts	NNS
.	.

Increasing	VBG
miR-21	NN
levels	NNS
promoted	VBD
,	,
whereas	IN
knocking	VBG
down	RP
miR-21	NN
attenuated	VBD
,	,
the	DT
pro-fibrogenic	JJ
activity	NN
of	IN
TGF-beta1	NN
in	IN
fibroblasts	NNS
.	.

A	DT
potential	JJ
mechanism	NN
for	IN
the	DT
role	NN
of	IN
miR-21	NN
in	IN
fibrosis	NN
is	VBZ
through	IN
regulating	VBG
the	DT
expression	NN
of	IN
an	DT
inhibitory	JJ
Smad	NN
,	,
Smad7	NN
.	.

These	DT
experiments	NNS
demonstrate	VBP
an	DT
important	JJ
role	NN
for	IN
miR-21	NN
in	IN
fibrotic	JJ
lung	NN
diseases	NNS
and	CC
also	RB
suggest	VBP
a	DT
novel	JJ
approach	NN
using	VBG
miRNA	NNP
therapeutics	NNS
in	IN
treating	VBG
clinically	RB
refractory	JJ
fibrotic	JJ
diseases	NNS
,	,
such	JJ
as	IN
IPF	NN
.	.

